Highlights
1 patent
About
Therapeutics for Oncology and Hematological Disorders
Biosight is a phase-2 clinical-stage biotechnology company developing therapeutics for Hematological Malignancies and disorders.
Biosight's lead product, BST-236 (INN aspacytarabine), is a proprietary anti-metabolite designed to enable high-dose therapy with reduced systemic toxicity. BST-236 is currently being investigated as a single agent in a phase-2b trial for first-line treatment of acute myeloid leukemia (AML), following a successful and encouraging phase-1/2a trial, which demonstrated tolerability with promising efficacy in AML patients unfit for standard therapy.
Identity
| Name | BioSight |
|---|---|
| Slug | biosight |
| Type / kind | startup |
| Crunchbase ID | biosight |
| Source _id | agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgL6Y9LoLDA |
Status
| Status | inactive |
|---|---|
| Status reason | Acquired (Inactive) by Ayala Pharmaceuticals on Oct 2023 - closed due to acquisition |
| Last update | 2026-05-17 |
Location
| HQ country code | IL |
|---|---|
| HQ region/district | Center District |
| HQ city | Lod |
| HQ address | HaYarden St 3, Lod, Israel |
Web & social
| https://www.linkedin.com/company/9423263 |
Classifications
Primary sector Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsCells
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business models
B2B
Tags
chemotherapycancerdrug-discoverybiopharmaceuticaltargeted-therapypharmaceuticalscancer-therapyoncologyhematology
Funding
| Total raised | $62.5M |
|---|---|
| Current stage | Acquired |
Raw source document
Show full JSON (0 KB)
{
"0": "s",
"1": "l",
"2": "i",
"3": "m",
"4": "p",
"5": "a",
"6": "g",
"7": "e",
"8": "s",
"9": "_",
"10": "i",
"11": "m",
"12": "p",
"13": "o",
"14": "r",
"15": "t"
}